Teva Pharmaceutical Industries announced the acceleration phase of its "Pivot to Growth" strategy at its 2025 Innovation & Strategy Day, outlining an ambitious roadmap to build a greater than $5 billion innovative medicines franchise by 2030. The Israeli pharmaceutical giant revealed five potential blockbuster drugs in its late-stage pipeline, each with peak sales potential exceeding $1 billion.
Strong Foundation Drives Growth Acceleration
The company has completed Phase 1 of its strategy, delivering nine consecutive quarters of growth fueled by strong momentum from key innovative growth drivers. Teva generated more than $2.3 billion in revenue in 2024 from its innovative portfolio, led by AUSTEDO (deutetrabenazine), AJOVY (fremanezumab), and UZEDY (risperidone).
"The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company – more focused, more innovative, and more robust," said Richard Francis, Teva's President and CEO. "Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio."
Blockbuster Pipeline Assets Target Major Therapeutic Areas
Teva's late-stage pipeline includes multiple assets with proven mechanisms and significant commercial potential:
Duvakitug (anti-TL1A) represents a potentially best-in-class treatment for inflammatory bowel disease, with potential expansion into additional indications and peak sales potential of $2-5 billion.
DARI is positioned as a dual-action rescue inhaler for asthma that could address a significant unmet need as the first ICS/SABA combination for both adult and pediatric patient populations, with peak sales potential of approximately $1 billion.
Emrusolmin stands out as a potential first-in-class treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease that currently has no approved treatments, with peak sales potential exceeding $2 billion.
TEV-408, an anti-IL-15 antibody, has received fast-track designation from the U.S. Food and Drug Administration for evaluation in celiac disease treatment, with peak sales potential exceeding $1 billion.
Olanzapine LAI is designed as a differentiated long-acting injectable for schizophrenia, expected to build on UZEDY's success and expand Teva's LAI franchise, with U.S. NDA filing expected in the second half of 2025.
Established Products Show Strong Growth Trajectory
The company's current innovative portfolio continues demonstrating robust performance. AUSTEDO is expected to exceed $2.5 billion in sales by 2027 and surpass $3 billion by 2030. AJOVY has established a global presence across 43 countries with expected launches in three additional countries this year.
The LAI schizophrenia franchise is projected to achieve $1.5-2.0 billion in peak sales, with UZEDY emerging as the fastest growing LAI, capturing more than 60% risperidone LAI market share.
Generics Business Maintains Market Leadership
Teva's generics, biosimilars, and OTC business remains a stable, robust cash-generating powerhouse. The company continues leading in generics globally with a strong pipeline of complex generics and biosimilars, including 13 biosimilars in development with potential for five new launches planned by 2027.
The company is expanding its $1.1 billion OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth while maintaining strategic focus on complex generics, biosimilars, and OTC to compensate for gRevlimid by 2027.
Financial Targets Reaffirmed Through 2030
Teva reaffirmed its 2027 financial targets, including revenue growth driven by innovative launches and stable generics business, operating margin expansion to 30% by 2027, and free cash flow exceeding $2.7 billion in 2027 and $3.5 billion by 2030. The company expects to achieve approximately $700 million in net savings through modernizing the organization and improving operational efficiencies, enabling reinvestment in R&D and commercial capabilities.
